Rituximab vs intravenous methylprednisolone
Palpebral aperture improvement (decrease) by 3 mm or more · thyroid‐associated ophthalmopathy
It is very uncertain whether summary of findings table ‐ Rituximab changes palpebral aperture improvement (decrease) by 3 mm or more compared with intravenous methylprednisolone (very low certainty).
1 finding from 1 review
- RR 5.31 [0.28, 102.38]1 study · 31 participantsVery low